SYGNIS AG: SYGNIS raises revenue guidance for 2018 after closing the acquisition of TGR Biosciences

Ad hoc release according to article 17 MAR
 

SYGNIS raises revenue guidance for 2018 after closing the acquisition of TGR Biosciences

Heidelberg, Germany and Cambridge, UK, 18 May 2018 - SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced that it has revised its guidance for the financial year 2018 following the recently announced acquisition of TGR Biosciences.

After assessing the impact of the TGR Biosciences acquisition on the expected results for 2018, SYGNIS has raised its 2018 full year revenue guidance to EUR13-14 million (previous revenue guidance: EUR11-12 million), an increase of at least 67% against 2017 reported revenues, and continues to expect an overall positive EBITDA for the year.

*** end of ad hoc announcement ***

For further information, please contact:

SYGNIS AG
Dr. Heikki Lanckriet
CEO/CSO
Phone: +44 1223 873 364
Email: heikki.lanckriet@sygnis.com

MC Services AG (Investor Relations and International Media Relations)
Dr. Claudia Gutjahr-Löser
Managing Director
Phone: +49 89 210228 0
Email: sygnis@mc-services.eu

About SYGNIS AG: www.sygnis.com
SYGNIS develops and commercialises value-added, easy-to-use, reliable products for genomics and proteomics research based on its proprietary technologies, offering a wide range of solutions that address key challenges in molecular biology. With applications spanning the entire molecular biology workflow, the Group's cutting-edge offerings include easy-to-use off-the-shelf products as well as custom services, supporting scientists from academia through to commercial manufacturing. SYGNIS' products are sold through a direct sales force and several distribution partners in Europe, the USA and Asia. SYGNIS AG has offices in Germany, Spain, UK, USA and Singapore which trade under the Expedeon brand. The Company is listed on the Prime Standard segment of the Frankfurt Stock Exchange (Ticker: LIO1; ISIN: DE000A1RFM03).

### This document is not a securities prospectus and the information contained herein does not constitute an offer to sell or a solicitation of an offer to purchase any securities of SYGNIS AG in the Federal Republic of Germany nor under any other jurisdiction, in particular not where such kind of offer or solicitation is prohibited or lacks the required permission. Potential investors in securities of SYGNIS AG are asked to familiarize themselves with and to observe the respective restrictions. The information in this document may not be disseminated outside the Federal Republic of Germany in particular not in the United States, to U.S. Persons (as defined in Regulation S of the U.S. Securities Act of 1933) or to publications with a general circulation in the United States with the exception of such disclosures or announcements outside the Federal Republic of Germany which have to be made under the respective mandatory law. Any person who fails to comply with these restrictions may violate the securities laws of certain jurisdictions, in particular of the United States. Securities in SYGNIS AG are not publicly offered outside the Federal Republic of Germany. Some statements included in this ad hoc announcement, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since, given their very nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in light of new information or future results or for any other reason. ###